Scientists map antibody binding sites on virus spike

The coronavirus immunotherapeutic consortium studied the effect of coronavirus spike mutations on hundreds of RBD-targeted antibodies. Key classes of antibodies maintained neutralisation activity against variants. The results will guide antibody therapy.
Twitter/La Jolla Institute

A new Covid-19 ‘antibody map’ is helping researchers identify antibodies that will be able to neutralise the coronavirus even after it mutates, according to a report published recently in journal Science.

Using hundreds of antibodies collected from Covid-19 survivors around the world, a global research team mapped out exactly where each antibody attaches to the spike protein on the virus surface, which it uses to break into cells and infect them.

The researchers looked for -- and found -- antibodies that target sites on the spike that are so important for the viral life cycle that the virus probably could not function without them.

Those sites are likely to remain targets for vaccines or treatments even when the virus mutates.

"If you are making an antibody cocktail, you'd want at least one of those antibodies in there because they are probably going to maintain their efficacy against most variants," said co-author Kathryn Hastie of the La Jolla Institute for Immunology in California, in a news release.